Organization
State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd
2 abstracts
Abstract
Mutational profiling of newly diagnosed glioblastoma to identify predictive biomarkers of efficacy and safety of anlotinib combination therapy.Org: Guangdong YueBei People's Hospital affiliated to Shantou University, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, The Second Clinical Medical College of Zhejiang Chinese Medical University, Affiliated Hospital of Xuzhou Medical University, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd,
Abstract
Serial ctDNA monitoring to predict response in mCRC patients treated with anlotinib in combination with oxaliplatin and capecitabine (CAPEOX) as the first-line therapy.Org: Cancer Center Zhejiang University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd,